Prognostic Analysis of 131I Efficacy After Papillary Thyroid Carcinoma Surgery Based on CT Radiomics

被引:1
|
作者
Cao, Huijun [1 ]
Shangguan, Linjue [2 ]
Zhu, Hanlin [3 ]
Hu, Chunfeng [1 ]
Zhang, Tong [1 ]
Han, Zhijiang [4 ]
Wei, Peiying [4 ]
机构
[1] Zhejiang Chinese Med Univ, Sch Clin Med 4, Hangzhou 310053, Peoples R China
[2] Hangzhou Canc Hosp, Hangzhou 310005, Peoples R China
[3] Hangzhou Ninth Peoples Hosp, Dept Radiol, Hangzhou 310012, Peoples R China
[4] Westlake Univ, Affiliated Hangzhou Peoples Hosp 1, Sch Med, 261 Huansha Rd, Hangzhou 310006, Peoples R China
来源
关键词
papillary thyroid carcinoma; Iodine-131; radiomics; predictive model; treatment outcome; STIMULATED THYROGLOBULIN LEVEL; CANCER; IMPACT; TOMOGRAPHY; ABLATION;
D O I
10.1210/clinem/dgae364
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To develop and validate a radiomics-clinical combined model combining preoperative computed tomography (CT) and clinical data from patients with papillary thyroid carcinoma (PTC) to predict the efficacy of initial postoperative I-131 treatment. Methods: A total of 181 patients with PTC who received total thyroidectomy and initial I-131 treatment were divided into training and testing sets (7:3 ratio). Univariate analysis and multivariate logistic regression were used to screen clinical factors affecting the therapeutic response to I-131 treatment and construct a clinical model. Radiomics features extracted from preoperative CT images of PTCs were dimensionally reduced through recursive feature elimination and least absolute shrinkage and selection operator. Logistic regression was used to establish a radiomics model, and a radiomics-clinical combined model was developed by integrating the clinical model. The area under the curve (AUC), sensitivity, and specificity were used to evaluate the prediction performance of each model. Results: Multivariate analysis revealed that pre-I-131 treatment serum thyroglobulin was an independent clinical risk factor affecting the efficacy of initial I-131 treatment (P = .002), and the AUC, sensitivity, and specificity for predicting the efficacy of initial I-131 treatment were 0.895, 0.899, and 0.816, respectively. After dimensionality reduction, 14 key CT radiomics features of PTCs were included. The established radiomics model predicted the efficacy of I-131 treatment in the training and testing sets with AUCs of 0.825 and 0.809, sensitivities of 0.828 and 0.636, and specificities of 0.745 and 0.944, respectively. The combined model improved the AUC, sensitivity, and specificity in both sets. Conclusion: The preoperative CT-based radiomics model can effectively predict the efficacy of initial postoperative I-131 treatment in patients with intermediate- or high-risk PTC, and the radiomics-clinical combined model exhibits better predictive performance.
引用
收藏
页码:3036 / 3045
页数:10
相关论文
共 50 条
  • [41] Incremental Prognostic value of Circulating CD4+T cell Subsets in the First 131I Treatment of Papillary Thyroid Carcinoma
    Fan, D.
    Shi, Z.
    Zhang, S.
    Xue, Y.
    Cheng, Z.
    Lu, X.
    Zhang, J.
    Hu, R.
    Li, C.
    Wu, L.
    Lu, K.
    Wang, H.
    Cheng, Y.
    Li, X.
    Wu, Z.
    Liu, H.
    Li, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S176 - S176
  • [42] Implications of mediastinal uptake of 131I with regard to surgery in patients with differentiated thyroid carcinoma
    Haveman, JW
    Phan, HTT
    Links, TP
    Jager, PL
    Plukker, JTM
    CANCER, 2005, 103 (01) : 59 - 67
  • [43] Molecular characteristics in papillary thyroid cancers (PTCs) with no 131I uptake
    Mian, Caterina
    Barollo, Susi
    Pennelli, Gianmaria
    Pavan, Nicodemo
    Rugge, Massimo
    Pelizzo, Maria Rosa
    Mazzarotto, Renzo
    Casara, Dario
    Nacamulli, Davide
    Mantero, Franco
    Opocher, Giuseppe
    Busnardo, Benedetto
    Girelli, Maria Elisa
    CLINICAL ENDOCRINOLOGY, 2008, 68 (01) : 108 - 116
  • [44] Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan
    Chung, JK
    So, Y
    Lee, JS
    Choi, CW
    Lim, SM
    Lee, DS
    Hong, SW
    Youn, YK
    Lee, MC
    Cho, BY
    JOURNAL OF NUCLEAR MEDICINE, 1999, 40 (06) : 986 - 992
  • [45] Treatment with 131I of thyroid remnants in a patient with papillary thyroid carcinoma and end-stage chronic renal failure
    Andres, A.
    Tardin, L.
    Santapau, A.
    Razola, P.
    Prats, E.
    Parra, A.
    Rivas, M. A.
    Ruiz, P.
    Alvarez, R.
    Camara, A.
    Banzo, J.
    REVISTA ESPANOLA DE MEDICINA NUCLEAR, 2010, 29 (01): : 32 - 35
  • [46] Analysis of the 131I therapy in the young and adolescent patients with differentiated thyroid carcinoma
    Wang, Jiantao
    Kuang, Anren
    JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (03)
  • [47] Thyroid cancer after exposure to radioactive 131I
    Holm, Lars-Erik
    ACTA ONCOLOGICA, 2006, 45 (08) : 1037 - 1040
  • [48] THYROID ANTIBODIES AFTER 131I TREATMENT FOR HYPERTHYROIDISM
    EINHORN, J
    FAGRAEUS, A
    JONSSON, J
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1965, 25 (09): : 1218 - +
  • [49] 131I Abnormal Uptake by the Thyroid Bed From Zuckerkandl Tubercle Diagnosis by 131I SPECT/CT
    Kawabe, Joji
    Higashiyama, Shigeaki
    Kotani, Kohei
    Onoda, Naoyoshi
    Shiomi, Susumu
    CLINICAL NUCLEAR MEDICINE, 2015, 40 (03) : 275 - 277
  • [50] THYROID CANCER AFTER 131I THERAPY FOR THYROTOXICOSIS
    STAFFURTH, JS
    BRITISH JOURNAL OF RADIOLOGY, 1966, 39 (462): : 471 - +